GlassScriptPhysician profile
Lance R Wehrle
NPI 1184919607
$1,189.69
in general payments reported to CMS, 2019-2025
26 companies · $81.77 in 2025
The $81.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.36 · 2020: $58.32 · 2021: $316 · 2022: $225 · 2023: $323 · 2024: $170 · 2025: $81.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $151.82 | 2022-2025 | |
| Amgen INC. | $86.85 | 2021-2024 | Evenity, Prolia, Repatha |
| Xeris Pharmaceuticals, INC. | $78.88 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $78.69 | 2020-2023 | Mounjaro |
| Abbott Laboratories | $59.23 | 2021-2023 | Freestyle Libre 3 |
| Averitas Pharma INC. | $58.26 | 2024 | Qutenza |
| Novo Nordisk INC | $56.91 | 2021-2024 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $44.24 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $41.35 | 2022-2023 | Trelegy Ellipta |
| Medtronic, INC. | $40.37 | 2023 | Minimed 780g |
| Dexcom, INC. | $39.30 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.58 | 2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Sunovion Pharmaceuticals INC. | $33.19 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.30 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.50 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $23.34 | 2020-2021 | |
| Inspire Medical Systems, INC. | $18.64 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $17.48 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2023 | Glassia |
| Ultragenyx Pharmaceutical INC. | $16.68 | 2020 | |
| Electromed, INC. | $15.61 | 2024 | Smartvest |
| Neurelis, INC. | $12.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.79 | 2021 | |
| Pfizer INC. | $11.61 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Wehrle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.